The munKNEE Pure-Play Psychedelic Drug Stock Index went up 24.0% in the last 3 weeks. Below is the performance of each of the constituents and noteworthy developments over the past 3 weeks:

1. Seelos Therapeutics* (SEEL): +74.1% to $3.76/share
   • Has been added to the North American Psychedelics Index
2. Field Trip Health* (FTRPF): +60.1% to $5.94/share
   • Reported favorable Q3, 2021 financial results
   • Has been added to the North American Psychedelics Index
   • Opened the world’s first research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics in Jamaica as part of its previously announced strategic partnership with the University of West Indies.
3. Novamind (NM): +48.6% to C$2.20/share
   • Announced that its common shares will begin trading on the OTC Pink Market under the symbol "NVMDF" effective February 19, 2021 with its common shares continuing to trade on the Canadian Securities Exchange under the symbol "NM".
4. Numinus Wellness* (LKYSF): +36.6% to $1.38/share
   • Has been added to the North American Psychedelics Index
   • Q1 2021 financials showed that its launching of compassionate access trials, and augmenting its clinical and research activity - two industry firsts - has expanded its industry presence in a meaningful way.
5. Mind Medicine* (MMEDF): +34.9% to $3.98/share
   • Announced that it will acquire HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring.
   • Has been added to the North American Psychedelics Index
   • Entered into a  partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
6. Compass Pathways* (CMPS): +21.2% to $53.12/share
   • Has been added to the North American Psychedelics Index
   • Expanded its Discovery Center through collaborations with laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin, to develop new, optimized psychedelic compounds to address unmet medical need with COMPASS becoming the exclusive licensee for all new compounds generated.
7. Red Light Holland* (TRUFF): +10.8% to $0.41/share
   • Has been added to the North American Psychedelics Index
   • Advisory Board Chairman, Bruce Linton, is helping TRUFF get positioned to capitalize on what the company sees as a coming global boom in psychedelics.
8. Havn Life*  (HAVLF): +8.5% to $0.77/share
   • Has been added to the North American Psychedelics Index
   • Announce a strategic partnership with neuroscience and technology leader, HealthTech Connex Inc., whereby Havn will be a preferred psychedelic supply partner for future clinical trials launched by HealthTech Connex's Centre for Neurology Studies and, in addition, HealthTech Connex will promote Havn Life's library of naturally derived compounds to its other clinical trial partners and be a preferred partner for the execution of Havn Life clinical trials.
9. Revive Therapeutics* (RVVTF) +6.8% to $0.47/share
   • Has been added to the North American Psychedelics Index
   • Entered into an asset purchase agreement with Newscope Capital to acquire the full rights to PharmaTher’s intellectual property pertaining to psilocybin for an aggregate consideration of up to C$10M.
10. Champignon Brands (SHRMF): +6.7% to $0.64/share
    • Announced that, after review, it would refile its condensed interim consolidated financial statements and management's discussion & analysis for the three- and six-month periods ended March 31, 2020. 
11. Jaguar Health (JAGX): +1.4% to $2.86/share
    • Announced its commitment to move forward with an exclusive relationship with the planned Dragon special purpose acquisition company and its support of the Dragon SPAC's intention for Napo EU, the anticipated subsidiary of the Company in Italy, to be the named target of the Dragon SPAC.
12. Mindset Pharma (MSSTF): +1.1% to $0.95/share
    • Began trading on the OTCQB Venture Market under the symbol "MSSTF" with its shares continuing to be listed on the Canadian Securities Exchange under the ticker symbol "MSET"
    • Has been added to the North American Psychedelics Index
    • Proof-of-Concept studies in animal models have shown that several of its proprietary, novel, and diverse psychedelic compounds are demonstrating strong potency and efficacy that is superior to psilocybin which represents a significant advancement in Mindset's development of its new psychedelic drug program.
13. Mind Cure Health* (MCURF): -6.0% to $0.47/share
    • Announced the release of its original nootropic and adaptogen product offerings which can now be ordered from the Company's website and are expected to begin shipping Feb. 23 .
    • Listed warrants for trading on CSE under the symbol "MCUR.WT". Each warrant entitles the holder to acquire one common share of the Company at an exercise price of $0.80 until February 10, 2026.
    • Has been added to the North American Psychedelics Index
14. Cybin* (CLXPF): -7.3% to $1.53/share
    • Announced its collaboration with neurotech pioneer HI LLC dba Kernel to quantify brain activity in real time during psychedelic experiences thereby adding another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction.
    • Has been added to the North American Psychedelics Index
15. Psyence Therapeutics (PSYG): -8.0% to C$0.46/share
    •  Entered into a Research Collaboration Agreement with MycoMeditations Inc., a leading psilocybin retreat provider, to conduct an observational study of the efficacy of naturally derived psilocybin.

* indicates that the stock is also a constituent in the new - and tradable - Horizons Psychedelic Stock Index ETF (PSYK) which began trading on the Canadian NEO Exchange on January 26th at C$9.43 and closed at C$11.25 this week up 21.8% as compared to the munKNEE Pure-Play Psychedelic Drug Stocks index which was up 24.0% from the beginning of the month. The Horizon Index, however, is not a pure-play ETF in that it also includes Johnson & Johnson, AbbVie Inc. and Greenbrook TMS Inc. who are not directing 100% of their efforts into the research and development of psychedelic components for medical applications. The  munKNEE Pure-Play Psychedelic Drug Stocks Index, on the other hand, is a pure-play and, as such, provides a true picture of the health and trend of this new stock sector. 

Please Note: Company names above have been hyperlinked to their corporate web sites and every company trading symbol has been hyperlinked to stock charts, in-depth financial data, and links to other articles on the company to enable the reader to do their due diligence before making a decision to invest in any stock mentioned. Also, keep in mind that some stocks in this sector trade for less than $1/share (i.e. are penny stocks) and may be susceptible to manipulation by unscrupulous speculators. All prices are in USD unless otherwise noted. Go here to convert to another currency.

Investing in small-cap stocks is speculative but, given the recent returns on psychedelic drug stocks, few investment opportunities of any kind, in any market, can equal the potential returns from this sector.